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Raltegravir (Isentress, MK-0518), developed by Merck, 
is the first HIV-1 integrase inhibitor (INI) approved by the 
FDA.1 Raltegravir and its congeners (Figure 1),1b,c 
elvitegravir (Gilead) and S/GSK candidates have similar 
pharmacophoric elements and mechanism of action.1d,e 
The interest of some of us in hydroxamates2a and the well-
known chelating power of hydroxamic acids,2b prompted us 
to propose alternative candidates based on the replacement of 
the C-OH group of raltegravir by a N-OH group, which 
would enhance the acidity of the OH proton and would 
improve the coordination with magnesium ions. Thus, we 
designed N-hydroxypyrimidinone derivatives shown in 
Figure 1 (bottom). The challenge was to develop a general 
approach, as simple as possible, to these unknown molecules. 
The strategies analyzed by us at the beginning of our 
project are summarised in Scheme 1. In the first approach 
(a), we envisaged the N-oxidation of N3 of 4-amino-
pyrimidines and of N1 of adenine,3 where the π-electron- 
donating ability of the amino group is crucial for the 
formation of the N-oxide. The subsequent deamination, 
either enzymatically or via diazotization,4 should afford the 
 
Figure 1. Raltegravir and two examples of congeners. N-Hydroxypyrimidin-
4-one derivatives proposed as alternative candidates. 
desired N-hydroxy pyrimidones (cyclic hydroxamic acids). 
While 2-cyano derivatives of adenine and adenosine 
(Scheme 1, top, X = CN)5 gave the N-oxide in acceptable 
conversions (with a large excess of m-CPBA in CH2Cl2, as 
the reagent of choice among eight reagents examined), the 
corresponding methyl ester (X = COOMe) and amide (X = 
CONHCH2C6H4F = CONH-4-FBn) did not. In other words, a 
slight increase in the steric hindrance at position 2 hampered 
the N-oxidation. Although we achieved the conversion of 
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Scheme 1.  Retrosynthetic analysis of N-hydroxypyrimidin-4-ones. 
X = CN to X = COOMe with NaOMe in MeOH at 50 ºC, the 
methoxy group could not be replaced by the 4-
fluorobenzylamino group (a substitution that was very easy 
when the N-oxide substituent was absent). Moreover, 
whereas deamination of adenine derivatives (to obtain 
hypoxanthine derivatives) was quite efficient in our hands, 
either with adenosine deaminase or via nitrosation, the N-
oxide derivatives did not react. In short, the route via 
formation of N-oxides is not feasible. 
Approach b involved a ring opening–ring closing process 
by using hydroxylamine (or a protected derivative of it, such 
as NH2OBn or NH2OTr) to attack the oxazinones of Scheme 
1. We prepared the corresponding imidazo-oxazinone6 by 
treatment of the o-amino carboxylic acid with a large excess 
of ClCOCOOMe and DIPEA in CH3CN. Opening with 
hydroxylamine derivatives gave mixtures coming from the 
attack of the hydroxylamines at the diverse electrophilic 
positions. Moreover, heating the open compounds in Ac2O 
gave rise to degradation compounds. 
According to disconnection c, the hydroxamates (PG = Bn 
or PG = 4-methoxybenzyl = PMB), prepared from the amino 
ester, benzylamine or 4-methoxybenzylamine, and LiN(SiMe3)2 
(LiHMDS), were heated with dimethyl oxalate and NaOEt,7 in 
search of direct cyclisation. Only starting material was 
recovered. Heating with MeOCO-CONH-4-FBn was also 
unsuccessful. With ClCOCOOMe and DIPEA or in pyridine, 
mainly the O-acylation occurred. On the other hand, with 
K2CO3 or with DMAP, NHCOCOOMe derivatives were 
obtained, but their cyclisation to N-hydroxypyrimidinones 
under several dehydrating conditions did not take place. 
Among all the approaches that we attempted only that one 
indicated as d in Scheme 1 turned out to be productive. 
Although the reaction of vicinal amino carboxamides with 
alkyl orthoformates such as CH(OR)3 is classical8 and 
orthoesters such as methyl 2,2,2-trimethoxyacetate9 have 
been used with vicinal diamines or aminophenols,9d,e there 
are no reported precedents, according to a SciFinder search, 
of the reaction of amino hydroxamates with this oxalic acid 
orthoester. We first examined the conversion of amino ester 
1a (methyl anthranilate) to benzohydroxamate 2a (Scheme 
2). An excess of a strong base such as LiHMDS was 
required.10 With a stronger base such as LDA the reaction 
was even faster.10 Without strong base the reaction did not 
progress, even in refluxing 1,4-dioxane. The more general 
conditions starting from amino esters 1a–e, the analogous 
pyridines 1g and 1h and the methyl 5-aminoimidazole-4-
carboxylate 1k11 are shown in Scheme 2, which gave rise to 
good-to-excellent yields of hydroxamates of type 2 (in the 
case of 1e, a mixture was obtained, but 2e and 2f were 
readily separated by column chromatography). On the other 
hand, owing to the decomposition of amino esters 1i and 1j 
in strong basic media, we prepared 2i and 2j by the standard 
coupling of the corresponding amino acids with O-(4-
methoxybenzyl)hydroxylamine (NH2OPMB) and 1-ethyl-3-
(3-dimethylaminopropyl)carbodiimide (EDC).12 
We then subjected 2a and (MeO)3CCOOMe excess to an 
screening of solvents, acid catalysts, temperatures, and 
reaction times. Most relevant results are shown in Table 1. 
 
Scheme 2.  Amino hydroxamates 2a–k. 
Table 1. 
Survey of cyclisation conditionsa 
 
Entry n Catalyst (mol%) Solvent Temp. (ºC) Time (h) Yield (%) 
  1 2.5 — DMF 90 15 ≤ 1 
  2 2.0 TsOH (10)b CH3CN 20   4 95 
  3 2.5 BF3·Et2O (10) CH3CN 20   4 97 
  4 2.5 BF3·Et2O (10) CH3CN 80   0.5 96 
  5 2.5 Sc(OTf)3 (10)c CH3CN 20   4 96 
  6 2.5 Sc(OTf)3 (10) CH3CN 80   0.5 95d 
  7 2.5 TsOH (10) CH3CN 80   0.5 98 
  8 2.5 TsOH (10) DMF 90   0.5 98 
  9 2.5 TsOH (10) dioxane 90   0.5 97 
10 2.5 TsOH (10) toluene 90   3 97 
11 2.5    AcOH 90   0.5 98 
12 2.0 TsOH (2) CH3CN 80   4 98 
a From 1 mmol of 2a in 10 mL of solvent. 
b TsOH means commercially available 4-toluenesulfonic acid–hydrate. 
c Scandium trifluoromethanesulfonate of 99% purity. In trials with 1 
mol% of TfOH, under the conditions of entry 5, only a conversion of 10% 
was noted after 72 h. Thus, the activity of Sc(OTf)3 is not due to the possible 
content of TfOH as impurity. 
d The O–PMB bond was cleaved under these conditions: the yield refers to 
PMB-deprotected 3a. 
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Acid catalysis was required, as expected for an orthoester, 
to achieve the complete conversion of 2a to 3a. Not only 
TsOH and Lewis acids were active, in several solvents (see 
entries 2–10 of Table 1), but also weaker acids such as 
AcOH could be used (entry 11). With 2 mol% of TsOH in 
refluxing CH3CN (entry 12), the cyclisation occurred in 4 h. 
This cyclisation or condensation is general, as it could be 
applied to 2-aminohydroxamates 2b–f, to aminopyridines 2g 
and 2h and to thiophene derivatives 2i and 2j, as indicated in 
Table 2, with some adaptations. Afterwards, the ester groups 
of 3a–j were transformed to carboxamides 4a–j,13 which 
were subjected to the cleavage of the O–PMB bond with 
TFA, to give the desired cyclic hydroxamic acids, 5a–j. 
Table 2. 
From amino esters 2a–j to quinazolinones 5a–f, pyridopyrimidinones 5g 
and 5h and thienopyrimidinones 5i and 5ja 
 
Entry Step 1 Yield (%) Step 2 Yield (%)b Step 3 Yield (%) 
1 2a to 3a  95–98 3a to 4a 91 4a to 5a 95 
2 2b to 3b 98 3b to 4b 86 4b to 5b 92 
3 2c to 3c 92 3c to 4c 87 4c to 5c 90 
4 2d to 3d 85 3d to 4d 85 4d to 5d 90 
5 2e to 3e 89 3e to 4e 89 4e to 5e 95 
6 2f to 3f 91 3f to 4f 93 4f to 5fc 97 
7 2g to 3g  90d 3f to 4g 85 4g to 5g 87 
8 2h to 3h  85e 3h to 4h 85 4h to 5h 92 
9 2i to 3i  92f 3i to 4i  70g 4i to 5i 90 
10 2j to 3j  90f 3j to 4j  75g 4j to 5j 92 
a See Scheme 2 for the substituents (groups/rings). 
b Similar results in refluxing THF. 
c The CONHOPMB group at position 4 of the aromatic ring was also 
cleaved to CONHOH. 
d 120 mol% of TsOH·H2O was required in this case, owing to the basicity 
of the 2-aminopyridine moiety. Refluxing AcOH was not sufficient whereas 
heating at 140 ºC (MW) gave rise to degradation. On the other hand, heating 
overnight with 10 mol % of BF3, at 80 ºC in a closed vial, caused an almost 
complete disappearance of 2g (to give in 80% isolated yield the desired 3g). 
e This cyclisation was performed in refluxing AcOH. 
f  For 2 h in refluxing CH3CN. 
g With 220 mol% of 4-FBnNH2 and dropwise addition of 200 mol% of 
LDA, in THF at –78 ºC, stirring for 4 h. Heating with 4-FBnNH2 (as in 
entries 1–8) gave rise to decarboxylation. 
Finally, we obtained N-hydroxyhypoxanthine 5k14 in 
three high-yielding steps from 2k as detailed in Scheme 3. 
Samples of the molecules thus prepared (5a, 5e, 5f and 
5k) were tested as inhibitors of the 3’-processing and strand 
transfer activities of HIV-1 integrase at a single 10 µM 
concentration, with regard to raltegravir;15a unfortunately, no 
activity was observed. They also appeared to be inactive for 
concentrations up to 10 µM in an HIV-1 antiviral, single-
round-of-infection assay.15b 
 
Scheme 3.  From 2k to 5k. Chemical shifts (dH in regular type, dC in 
italics). Assignments confirmed by 2D NMR (HSQC). 
In summary, we have synthesised new benzo-, pyrido-, 
thieno- and imidazo-fused N-hydroxypyrimidinones 
(quinazolinone, piridopyrimidinone, thienopyrimidinone 
and hypoxanthine ring systems) with carboxyl derivatives 
at position 2. The optimized sequence involves the reaction 
of ester groups with NH2OPMB and a strong base (LDA or 
LiHMDS) as well as a crucial acid-catalyzed condensation 
of these amino hydroxamates with methyl trimethoxy-
acetate, which has been carefully investigated to provide 
excellent yields of the cyclic compounds under very mild 
conditions. Overall, the protocol reported here for the first 
time for the synthesis of N-hydroxypyrimidinones 5a–k (4 
steps, most of them in 85–98% yields, up to 76% overall 
yield) appears to be of wide scope. In short, in the 
unsuccessful search for new antiviral drugs we have 
developed the best procedure to date for reaching hitherto 
unknown pyrimidinone-2-carboxylic acid derivatives, 
which may enjoy other applications.16 
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